Apogee Therapeutics (NASDAQ:APGE) Given Buy Rating at BTIG Research

BTIG Research reissued their buy rating on shares of Apogee Therapeutics (NASDAQ:APGE) in a research note released on Monday,Benzinga reports. BTIG Research currently has a $137.00 price target on the stock.

APGE has been the topic of several other research reports. Truist Financial began coverage on shares of Apogee Therapeutics in a research note on Tuesday, March 17th. They issued a “hold” rating and a $83.00 price objective on the stock. Wedbush increased their target price on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, March 3rd. Wolfe Research began coverage on shares of Apogee Therapeutics in a report on Wednesday, January 7th. They set a “peer perform” rating for the company. UBS Group upgraded shares of Apogee Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 7th. Finally, Wall Street Zen cut Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Apogee Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $103.92.

Apogee Therapeutics Stock Up 20.0%

Shares of Apogee Therapeutics stock opened at $79.24 on Monday. The business has a fifty day simple moving average of $71.28 and a 200-day simple moving average of $63.70. Apogee Therapeutics has a fifty-two week low of $26.20 and a fifty-two week high of $84.56. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of -18.78 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.02. Analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total transaction of $1,495,600.00. Following the transaction, the chief executive officer directly owned 1,152,987 shares of the company’s stock, valued at approximately $86,220,367.86. The trade was a 1.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the transaction, the director directly owned 298,647 shares in the company, valued at $22,786,766.10. The trade was a 85.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,839,700 shares of company stock worth $140,118,083 in the last 90 days. Company insiders own 42.77% of the company’s stock.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. acquired a new position in shares of Apogee Therapeutics in the fourth quarter worth $25,000. ANTIPODES PARTNERS Ltd boosted its position in Apogee Therapeutics by 41.2% during the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Apogee Therapeutics in the fourth quarter valued at about $37,000. Quantbot Technologies LP purchased a new position in Apogee Therapeutics in the third quarter valued at about $96,000. Finally, Seven Fleet Capital Management LP acquired a new position in Apogee Therapeutics in the 4th quarter worth about $136,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Key Headlines Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Phase 2 APEX Part A 52‑week results showed durable maintenance and deepening of responses with both every‑3‑month and every‑6‑month dosing (EASI‑75 maintenance ~75% and 85%; high rates of vIGA 0/1). The long durability and infrequent dosing profile are being viewed as differentiating for atopic dermatitis and drive the rally. GlobeNewswire: Positive Phase 2 Part A Data
• Positive Sentiment: Market/press coverage amplified the data release (Benzinga, MSN, Yahoo, Investing), increasing investor attention and trading volume. Media highlights emphasized strong maintenance rates and durable itch/lesional improvements. Benzinga: Data Readout Coverage
• Positive Sentiment: Analyst support: BTIG reaffirmed a Buy and set a $137 price target, providing a high upside reference for investors and likely supporting buying interest. Benzinga: BTIG Rating
• Positive Sentiment: Independent research/analysis (Seeking Alpha) reiterates a bullish thesis around infrequent dosing and a robust cash position, valuing APGE on a DCF basis and framing zumilokibart as a potential market disruptor—supports longer‑term investor optimism. Seeking Alpha: Buy Thesis
• Neutral Sentiment: Management hosted a conference call and published the 52‑week transcript to discuss the APEX data; this provides detail for investors but is informational rather than directional by itself. Seeking Alpha: Data Transcript
• Neutral Sentiment: Reported short‑interest figures in the feed are inconsistent/zero and do not appear to be a meaningful driver today; elevated volume vs. average suggests event‑driven trading rather than short covering alone.
• Negative Sentiment: Apogee announced a proposed $300M underwritten public offering of common stock (with a 30‑day option for up to $45M more). Issuing new shares could be dilutive and typically puts downward pressure on near‑term share price despite funding runway benefits. GlobeNewswire: Proposed $300M Offering

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.